We thank you for your attention and know this is a challenging time for all. It is also a challenging time for the dissemination of cutting-edge science and guidelines as we are forced to transition to novel forms of communication.
In this regard, we hope that the following report is a helpful and informative summary of the recent European Society of Cardiology Virtual Congress. You will find a summary of recent guideline updates, summaries of selected Hot Line Presentations, and key updates on COVID and Cardiovascular disease.
We hope that this reference helps to keep you informed and we are grateful for your readership. Most of all, we hope that all of you, your families and loved ones are safe and healthy and we thank all of you helping to care for the global community for your contributions.
Marc P. Bonaca
Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.
Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.
Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.
Conflict of Interest Statement:
Grant support to BWH from AstraZeneca, MedImmune, Merck, Pfizer
Grant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi
« 2020 Atrial Fibrillation Guidelines Next Article
Universal gene tests better than targeted for cancer patients »